Here's our take on what matters most today. Axsome Therapeutics (AXSM) surged an impressive +18.96% to close at $177.00, marking a significant outlier in a session where benchmark ETFs like SPY, QQQ, and DIA experienced minor pullbacks, closing at $687.01 (-0.12%), $619.43 (-0.23%), and $483.59 (-0.21%) respectively. This robust performance by AXSM followed Needham's decision to maintain a 'Buy' rating and raise its price target
AXSM Surges +18.96% to $177.00 as Broader Market ETFs See Modest Declines
AI-generated editorial content. For informational purposes only. Not financial advice.
Axsome Therapeutics leads gains with a nearly 19% jump, while SPY, QQQ, and DIA register minor losses in a session driven by company-specific news.
MoonshotScore AI Ratings
AI EnhancedOur AI analyzes fundamentals, momentum, and sentiment to score each stock 0-100.

Frequently Asked Questions
Why did Axsome Therapeutics (AXSM) stock surge today?
AXSM stock surged nearly 19% after Needham maintained a 'Buy' rating and raised its price target for Axsome Therapeutics. This positive analyst action drove significant investor interest, making it an outlier in a declining market.
What was AXSM's closing price and percentage gain?
Axsome Therapeutics (AXSM) closed at $177.00, marking an impressive gain of +18.96%. This strong performance contrasted sharply with minor pullbacks seen in broader market ETFs like SPY, QQQ, and DIA.
How did the broader market perform compared to AXSM?
While AXSM surged, benchmark ETFs SPY, QQQ, and DIA experienced minor pullbacks, closing down by -0.12%, -0.23%, and -0.21% respectively. AXSM's rally was driven by company-specific news, defying the general market trend.